<DOC>
	<DOCNO>NCT02066662</DOCNO>
	<brief_summary>The following trial hypothesis prove : In patient atrial fibrillation and/ pulmonary embolism standard anticoagulant treatment coumadin/phenprocoumon associate accelerate coronary valvular calcification assess cardiac compute tomography compare new anticoagulant therapy rivaroxaban .</brief_summary>
	<brief_title>Rivaroxaban Compared Vitamin K Antagonist Upon Development Cardiovascular Calcification</brief_title>
	<detailed_description>A single center , prospective , control , open , randomize , interventional clinical trial blind concern outcome measurement two- arm parallel group design perform investigate association rivaroxaban compare coumadin/phenprocoumon treatment OAT patient atrial fibrillation / pulmonary embolism regard development progression coronary artery calcification ( CAC ) aortic valve calcification ( AVC ) assess multi-slice spiral compute tomography scanning ( MSCT ) within one year follow-up . In total 253 patient ( 126 patient per treatment arm include calculate drop out invalid case ) atrial fibrillation and/ pulmonary embolism indication oral anticoagulation therapy enrol . After screen first cardiac CT scan perform order validate calcium score &gt; 50 inclusion criterion . If patient match inclusion/exclusion criterion remain imaging procedure ( Echocardiography , Intima Media Thickness carotid artery ( IMT ) Flow Mediated Vasodilatation ( FMD ) , Electrocardiography ( ECG ) blood pressure execute . Pregnancy strip test execute also serum chemistry , hematology , coagulation batch analysis perform . Patients randomize one two arm ( Rivaroxaban Marcumar ) undergo examination measurement describe 1 week , 1 , 6 , 9 12 month Follow- Up ( FU ) . In case positive result respect primary endpoint FU 2 year perform optionally .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Calcinosis</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Phenprocoumon</mesh_term>
	<criteria>1 . Male female patient age &gt; 18 year 2 . Need longterm OAT accord current international guideline treatment atrial fibrillation ( ACC/ ( American Heart Association [ AHA ] / European Society Cardiology [ ESC ] guideline ) / pulmonary embolism ( ACCP/ESC guideline ) . 3 . Existent Coronary Valvular Calcification , Agatston Score &gt; 50 least one location assess MSCT Screening 4 . The anticipated minimum life expectancy is18 month 1 . Patient clinical condition allow initiation longterm OAT include contraindication hypersensitivity active ingredient excipients , clinically relevant acute bleeding risk circumstance accord Summary Medicinal Product ( SmPC ) warning preventive measure precaution describe kept . 2 . Hypersensitivity active substance investigate excipients 3 . Patients previous coronary stent implantation Valvular Calcification Agatston Score &gt; 50 4 . Chronic kidney disease ( CKD ) Stage V ( GFR &lt; 15 mL ) 5 . Liver disease coagulopathy bleeding disorder include cirrhotic patient Child Pugh B C 6 . Acute gastrointestinal disease 7 . Clinically significant active bleeding 8 . Alcohol , opioids drug abuse 9 . Mental condition render patient unable understand nature , scope possible consequence study 10 . Patient unwilling unable give inform consent 11 . Patient unlikely comply protocol , e.g . uncooperative attitude , inability return followup visit , unlikelihood complete study 12 . Participation parallel interventional clinical trial 13 . Patient committed institution legal regulatory order 14 . Pregnant lactate woman 15 . Female patient capable bearing child without highly effective method birth control 16 . Patient receive concomitant treatment strong concurrent Cytochrome P 450 3A4 ( CYP3A4 ) P glycoprotein ( Pgp ) inhibitor , i.e . azoleantimycotics ( ketoconazole , itraconazole ) human immunodeficiency virus ( HIV ) protease inhibitor 17 . Neuraxial Anaesthesia spinal/epidural puncture 18 . Known Endocarditis 19 . Known Lactose intolerance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Coronary Valvular Calcification</keyword>
	<keyword>Agatston Score</keyword>
	<keyword>Rivaroxaban</keyword>
	<keyword>Coumarin</keyword>
	<keyword>Oral Anticoagulation Therapy ( OAT )</keyword>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>Pulmonary Embolism</keyword>
</DOC>